This report was first published by Endpoints News. To see the original version, click here
Two years ago at the European Society for Medical Oncology’s annual meeting, a prominent oncologist predicted that the 2020s would be the “decade of the ADCs.”
There were several high-value ADC-focused deals in 2023 ahead of that meeting, a trend that continued through the rest of 2023 and into 2024.
您已閱讀8%（390字），剩余92%（4646字）包含更多重要信息，訂閱以繼續探索完整內容，并享受更多專屬服務。